IOVA IOVANCE BIOTHERAPEUTICS, INC.

P/E --
Forward P/E --
Price/Sales 20.52
Beta 0.757
Div Yield --
Market Cap --

Company Analysis

Latest News

Iovance Biotherapeutics' second quarter revenue reached $99M as Amtagvi sales drive 66% growth

Iovance Biotherapeutics' second quarter revenue reached $99M as Amtagvi sales drive 66% growth

Iovance Biotherapeutics reported record financial results for the second quarter 2026, characterized by the accelerating commercial adoption of Amtagvi. The...